A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Senior Senator for Minnesota. Democrat.
Last Updated: Jan 9, 2019
Length: 20 pages
116th Congress (2019–2021)
This bill was introduced on January 9, 2019, in a previous session of Congress, but it did not receive a vote.
Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).
7 Cosponsors (4 Republicans, 3 Democrats)
Ordered Reported — Apr 30, 2019
What legislators are saying
“Two Central Oregon Irrigation Districts, joined by U.S. Senator Jeff Merkley and NRCS Chief Matthew Lohr, celebrate key milestones in $50 million project upgrading rural infrastructure, serving as national model for protecting farms and water resources”
— Sen. Jeff Merkley [D-OR] on Mar 20, 2019
Dec 19, 2018
Earlier Version — Introduced
This activity took place on a related bill, S. 3792 (115th).
Jan 9, 2019
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
Jul 29, 2021
Reintroduced Bill — Ordered Reported
This activity took place on a related bill, S. 1428.
S. 64 (116th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number S. 64. This is the one from the 116th Congress.
This bill was introduced in the 116th Congress, which met from Jan 3, 2019 to Jan 3, 2021. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2021). S. 64 — 116th Congress: Preserve Access to Affordable Generics and Biosimilars Act. Retrieved from https://www.govtrack.us/congress/bills/116/s64
“S. 64 — 116th Congress: Preserve Access to Affordable Generics and Biosimilars Act.” www.GovTrack.us. 2019. September 16, 2021 <https://www.govtrack.us/congress/bills/116/s64>
Preserve Access to Affordable Generics and Biosimilars Act, S. 64, 116th Cong. (2019).
|title=S. 64 (116th)
|accessdate=September 16, 2021
|author=116th Congress (2019)
|date=January 9, 2019
|quote=Preserve Access to Affordable Generics and Biosimilars Act
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.